FI112081B - Förfarande för framställning och rening av ny antineoplastisk cytokin - Google Patents
Förfarande för framställning och rening av ny antineoplastisk cytokin Download PDFInfo
- Publication number
- FI112081B FI112081B FI944907A FI944907A FI112081B FI 112081 B FI112081 B FI 112081B FI 944907 A FI944907 A FI 944907A FI 944907 A FI944907 A FI 944907A FI 112081 B FI112081 B FI 112081B
- Authority
- FI
- Finland
- Prior art keywords
- oncoinhibin
- cells
- human
- growth
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (7)
1. Förfarande för framställning av onkoinhibinpro-tein som utsöndras av mänskliga erytroblastoidceller och 5 som har en molekylmassa pä ca 2 8 kDa, är stabil inom ett pH-omräde pä ca 2 - 8 och ett temperaturomräde pä ca 4 -100 °C, och har antineoplastisk aktivitet, känneteck-n a t av att man inkuberar mänskliga erytroblastoidceller; 10 inducerar produktionen av onkoinhibin; och tar tillvara supernatanterna av cellodlingarna.
2. Förfarande enligt patentkrav 1, känneteck-nat av att proteinet är väsentligen fritt frän orenheter.
3. Förfarande enligt patentkrav 1, känneteck-15 n at av att proteinproduktionen gynnas av forbolester.
4. Förfarande enligt patentkrav 1, känneteck-nat av att proteinet är aktivt i standardbestämningar av onkoinhibin och väsentligen homogent enligt SDS-PAGE.
5. Förfarande enligt patentkrav 1, känneteck-20 nat av att man framställer mänskligt onkoinhibin som in- nehäller en immunomodulator för aktivering av lymfocyter, monocyter och neutrofiler för att döda tumörceller. * .·**. 6. Förfarande enligt patentkrav 1, känneteck- I · i nat av att man framställer mänskligt onkoinhibin som in- • * t 25 nehäller en tillväxtf aktor för att stimulera tillväxten hos normala celler.
7. Förfarande för rening av onkoinhibinprotein som utsöndras av mänskliga erytroblastoidceller och som har en molekylmassa pä ca 28 kDa, är stabil inom ett pH-omräde pä 30 ca 2 - 8 och ett temperaturomräde pä ca 4 - 100 °C, och har antineoplastisk aktivitet, kännetecknat av att man I I 1191)8-, ultrafiltrerar supernatanter av cellodlingar in-nehällande mänskligt onkoinhibin; dialyserar de ultrafiltrerade supernatanterna; utför DEAE Affigel Blue -kromatografi; 5 utför elektrofores med natriumdodekylsulfat - polyakrylamidgel och högtrycksvätskekromatografi med om-vänd fas. • ♦ 4 » • · * ·
4. I f ) · ♦ · *
4. I i t < I « 4 I » I i t 4 4
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87430892 | 1992-04-24 | ||
| US07/874,308 US5241051A (en) | 1992-04-24 | 1992-04-24 | Oncoinhibin |
| PCT/US1993/003828 WO1993022346A1 (en) | 1992-04-24 | 1993-04-23 | A novel anti-neoplastic cytokine |
| US9303828 | 1993-04-23 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI944907A FI944907A (sv) | 1994-10-19 |
| FI944907A0 FI944907A0 (sv) | 1994-10-19 |
| FI112081B true FI112081B (sv) | 2003-10-31 |
Family
ID=25363462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI944907A FI112081B (sv) | 1992-04-24 | 1994-10-19 | Förfarande för framställning och rening av ny antineoplastisk cytokin |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5241051A (sv) |
| EP (1) | EP0637319B1 (sv) |
| JP (1) | JP3434511B2 (sv) |
| KR (1) | KR950701347A (sv) |
| CN (1) | CN1068335C (sv) |
| AT (1) | ATE209500T1 (sv) |
| AU (1) | AU671637B2 (sv) |
| CA (1) | CA2118498C (sv) |
| DE (1) | DE69331231T2 (sv) |
| FI (1) | FI112081B (sv) |
| IL (1) | IL105473A (sv) |
| NO (1) | NO313099B1 (sv) |
| NZ (1) | NZ252429A (sv) |
| RU (1) | RU2139087C1 (sv) |
| SA (1) | SA93140393B1 (sv) |
| TW (1) | TW372873B (sv) |
| WO (1) | WO1993022346A1 (sv) |
| ZA (1) | ZA932830B (sv) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5993798A (en) * | 1992-04-24 | 1999-11-30 | Research Development Foundation | Oncoinhibin and methods of pharmaceutical use |
| PT914043E (pt) * | 1996-04-03 | 2004-02-27 | Rogosin Inst | Perolas de agarose-colagenio implantaveis contendo celulas que produzem um produto biologico difusivel e suas utilizacoes |
| RU2659684C2 (ru) * | 2012-01-18 | 2018-07-03 | Байосаксесс Байотек Ко. Лтд. | Композиции и способы применения форболовых сложных эфиров |
| CN116041514A (zh) | 2016-06-06 | 2023-05-02 | 希望之城 | Baff-r抗体及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6463395A (en) * | 1987-05-04 | 1989-03-09 | Oncogen | Oncostatin m and novel composition having antitumor activity |
| JPH04502769A (ja) * | 1989-04-10 | 1992-05-21 | オンコーゲン リミテッド パートナーシップ | オンコスタチンｍを使用したヒト内皮細胞増殖およびエフェクター機能の制御法 |
-
1992
- 1992-04-24 US US07/874,308 patent/US5241051A/en not_active Expired - Lifetime
-
1993
- 1993-04-21 IL IL10547393A patent/IL105473A/en not_active IP Right Cessation
- 1993-04-22 ZA ZA932830A patent/ZA932830B/xx unknown
- 1993-04-23 DE DE69331231T patent/DE69331231T2/de not_active Expired - Fee Related
- 1993-04-23 WO PCT/US1993/003828 patent/WO1993022346A1/en active IP Right Grant
- 1993-04-23 JP JP51939593A patent/JP3434511B2/ja not_active Expired - Fee Related
- 1993-04-23 RU RU94045922A patent/RU2139087C1/ru not_active IP Right Cessation
- 1993-04-23 EP EP93910750A patent/EP0637319B1/en not_active Expired - Lifetime
- 1993-04-23 TW TW082103154A patent/TW372873B/zh active
- 1993-04-23 NZ NZ252429A patent/NZ252429A/en unknown
- 1993-04-23 AU AU41135/93A patent/AU671637B2/en not_active Ceased
- 1993-04-23 AT AT93910750T patent/ATE209500T1/de not_active IP Right Cessation
- 1993-04-23 CA CA002118498A patent/CA2118498C/en not_active Expired - Fee Related
- 1993-04-24 CN CN93106355A patent/CN1068335C/zh not_active Expired - Fee Related
- 1993-11-30 SA SA93140393A patent/SA93140393B1/ar unknown
-
1994
- 1994-10-19 FI FI944907A patent/FI112081B/sv not_active IP Right Cessation
- 1994-10-19 NO NO19943968A patent/NO313099B1/no unknown
- 1994-10-21 KR KR1019940703739A patent/KR950701347A/ko not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0637319B1 (en) | 2001-11-28 |
| WO1993022346A1 (en) | 1993-11-11 |
| ATE209500T1 (de) | 2001-12-15 |
| AU4113593A (en) | 1993-11-29 |
| EP0637319A1 (en) | 1995-02-08 |
| DE69331231D1 (de) | 2002-01-10 |
| IL105473A0 (en) | 1993-08-18 |
| AU671637B2 (en) | 1996-09-05 |
| EP0637319A4 (en) | 1997-06-11 |
| RU2139087C1 (ru) | 1999-10-10 |
| DE69331231T2 (de) | 2002-08-22 |
| SA93140393B1 (ar) | 2006-05-23 |
| US5241051A (en) | 1993-08-31 |
| IL105473A (en) | 1998-09-24 |
| NO943968L (no) | 1994-10-19 |
| FI944907A (sv) | 1994-10-19 |
| JPH07506364A (ja) | 1995-07-13 |
| CA2118498A1 (en) | 1993-11-11 |
| TW372873B (en) | 1999-11-01 |
| RU94045922A (ru) | 1997-05-10 |
| FI944907A0 (sv) | 1994-10-19 |
| NO313099B1 (no) | 2002-08-12 |
| CA2118498C (en) | 2005-06-21 |
| ZA932830B (en) | 1994-11-22 |
| JP3434511B2 (ja) | 2003-08-11 |
| NO943968D0 (no) | 1994-10-19 |
| KR950701347A (ko) | 1995-03-23 |
| CN1083389A (zh) | 1994-03-09 |
| CN1068335C (zh) | 2001-07-11 |
| NZ252429A (en) | 1996-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2107728C1 (ru) | Способ получения человеческого иммунного интерферона | |
| Matsuda et al. | Identification of alpha 2-macroglobulin as a carrier protein for IL-6. | |
| FI77877C (sv) | Förfarande för framställning och rening av human Le-formig interferonp rotein. | |
| Cameron et al. | Purification to homogeneity and amino acid sequence analysis of two anionic species of human interleukin 1. | |
| JP4077876B2 (ja) | ケモカイン結合タンパク質およびその使用 | |
| Ralph et al. | Biological properties and molecular biology of the human macrophage growth factor, CSF-1 | |
| Prestidge et al. | Biochemical comparison of murine colony-stimulating factors secreted by a T cell lymphoma and a myelomonocytic leukemia. | |
| Andus et al. | Discrimination of hepatocyte‐stimulating activity from human recombinant tumor necrosis factor α | |
| FI112081B (sv) | Förfarande för framställning och rening av ny antineoplastisk cytokin | |
| Olsson et al. | Biochemical properties of the eosinophil cationic protein and demonstration of its biosynthesis in vitro in marrow cells from patients with an eosinophilia | |
| FI91484C (sv) | Förfarande för framställning av en ny celltillväxtreglerande faktor onkostatin M | |
| Fresno et al. | Proteins synthesized by inducer T cells: evidence for a mitogenic peptide shared by inducer molecules that stimulate different cell types | |
| US5993798A (en) | Oncoinhibin and methods of pharmaceutical use | |
| Leslie et al. | Growth factor gene activation and clonal heterogeneity in an autostimulatory myeloid leukemia | |
| ADOLF et al. | Constitutive production of interferon-α2 by a human B-lymphoblastoid cell line | |
| Pestka et al. | The human interferons | |
| Sancéau et al. | Interferon-β2 (BSF-2) mRNA is expressed in human monocytes | |
| Ishibashi et al. | Tumor necrosis factor-β and hypercalcemia | |
| Kull Jr et al. | Macrophage cytotoxin: Sources and mechanism | |
| CN117205303A (zh) | 细胞因子csbf在治疗银屑病中的应用 | |
| FI98373C (sv) | Ny diagnostiskt användbar polypeptid, onkostatin M | |
| Shabo | Studies on the molecular control of cell differentiation in myeloid leukemic cells | |
| Grenett | Cloning and regulation of murine interleukin-6 gene expression | |
| EP0399777A2 (en) | Hematopoietic growth factor derived from T lymphocytes and methods of use therefor | |
| MATTHEWS et al. | LYMPHOKINES, VOL. 14 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |